Healthtech Startups

MiRNDa, Inc. is a Japanese biotech company developing in-vitro diagnostic (IVD) medical devices based on RNA modification technology to detect an early "stage 0" of cancer.

1 investor

Melody International develops mobile fetal and maternal monitoring medical devices, including the "iCTG" cardiotocograph and the "Central i" central monitoring system for perinatal care. The Japanese company provides remote maternal and fetal health monitoring for healthcare providers, with device registrations in Japan and international markets such as Thailand, Kenya, the Philippines, and Indonesia.

1 investor

Yakkle is an online medical service offering convenient digital healthcare for chronic disease management. The platform enables patients to consult with fixed physicians via LINE without appointments, receive medications at home, and conduct at-home blood tests for conditions like hypertension and diabetes.

1 investor

LEBER is a smartphone app offering a "doctor sharing platform" that lets users consult with physicians 24/7 and monitor their health. It is marketed to employers as a way to support employee health.

1 investor

A company developing radioactive pharmaceuticals for cancer treatment with enhanced visibility. The company focuses on accelerating the delivery of innovative diagnostic and therapeutic agents to patients and healthcare providers.

1 investor

Logic Inc. develops software solutions for the construction and healthcare sectors, including building design CAD tools, renovation simulation software, and home care management systems. The company also operates digital catalog platforms and has earned multiple patents in its core product areas.

1 investor

Shanghai/Nanjing Sansheng Biotechnology develops, manufactures, and sells cell preservation products and related services, supporting cell therapy for medical and research institutions. Its offerings include cell cryopreservation agents used as pharmaceutical excipients, serving over 200 healthcare and research organizations in China.

1 investor

Shanghai Cell Therapy Group develops cell-therapy technologies and products aimed at curative treatment of tumors and aging-related diseases, including CAR-T therapies such as a non-lymphodepleting three-target CAR-T and a PD1 nanobody mesothelin-targeting CAR-T. The company also works on cell rejuvenation approaches to prevent and intervene in aging-related conditions, with operations in China.

1 investor

Guangdong HEC Pharmaceutical, founded in 2003, is a comprehensive pharmaceutical company engaged in the R&D, manufacturing, and commercialization of drugs, with a focus on innovative drugs as well as improved new drugs, generics, and biosimilars. The company concentrates on therapeutic areas including infectious diseases, chronic diseases, and oncology.

1 investor

TaiMed Biologics is a Taiwan-based biopharmaceutical company that develops monoclonal antibody therapies for HIV, including the long-acting TMB-365/TMB-380 combination and the CD4-targeted ADC platform extending into autoimmune diseases. It also operates a cGMP protein manufacturing facility and provides CDMO services such as process development, analytical method development, formulation development, and commercial manufacturing for antibody products.

1 investor

Zhejiang Fert Medical Device is a Chinese manufacturer of sterile, single-use medical equipment, including disposable anesthesia and pain consumables, precision infusion sets, nursing consumables, and connectors and filters. It handles research, production, and sales of these devices for healthcare use.

1 investor

Guangdong Raynovent Biotech is a biotech company focused on discovering, developing, and commercializing innovative drugs for respiratory and metabolic diseases. Founded in October 2018 and headquartered in Guangzhou, China, its pipeline includes treatments for viral infections, type 2 diabetes, obesity, and MASH.

1 investor

UE World (优亿医疗) develops visualization-based medical devices and systems for anesthesia, respiratory, and gastrointestinal care, including airway management tools and endoscopy technology with intelligent and remote diagnostic capabilities. Founded in 2010, the China-based company handles research, manufacturing, sales, and service as a national high-tech enterprise.

1 investor

Shanghai General Healthy Information & Technology develops intelligent medical logistics and automation equipment, including automated pharmacy dispensing systems marketed under the CONSIS and SANTO brands, for hospitals. Its products are used by over 1,000 large and medium-sized hospitals across more than 30 provinces in China.

1 investor

Beijing-based Challenbio (北京层浪生物科技有限公司), founded in 2020, develops, manufactures, and sells IVD diagnostic instruments and reagents along with biomedical research instruments, with a focus on flow cytometry systems and automation. Its products serve both clinical diagnostics and scientific research markets in China.

1 investor

Wisonic (华声医疗) develops ultrasound imaging systems and related medical devices, including 5G cloud-connected and AI-assisted ultrasound for emergency, anesthesia/pain, prenatal screening, and remote diagnosis applications. The company serves hospitals and clinical users, with a research, manufacturing, sales, and service network across China and offices in the US, Germany, and Hong Kong.

1 investor

Capital Biotech (博奥晶典) operates a high-throughput biotechnology service platform in China, developing molecular diagnostics products including prenatal screening and diagnostic tests for birth defect prevention. It also provides genetic testing and forensic DNA identification services for public-health and government programs.

1 investor

HerAnova develops non-invasive, blood-based diagnostics and treatments for endometriosis and infertility, aimed at improving women's health. It is building a suite of tests, including a blood-based test for detecting and confirming endometriosis.

1 investor

Hubei Topgene Biotechnology is a CRO founded in 2009 that specializes in large-animal studies and focuses on preclinical drug research and evaluation, offering nonclinical safety, pharmacodynamics, pharmacokinetics, bioanalysis, molecular imaging, medical device evaluation, and non-human primate breeding services. It serves innovative drug developers with GLP laboratories meeting Chinese NMPA, US FDA, EU OECD, and Australian TGA standards.

1 investor

Taimei provides an online training platform for the pharmaceutical industry, supporting course deployment, test banks, exams, and certification management. It emphasizes regulatory compliance, including ISO certification and Title 21 CFR Part 11 electronic signature standards, with reporting and audit-ready training records.

1 investor

A research-driven specialty pharmaceutical company that develops and commercializes innovative medicines through the 505(b)(2) regulatory pathway, focusing on central nervous system disorders, metabolic diseases, and orphan indications. The company operates in New Jersey and Shanghai, leveraging established molecules with proven safety profiles.

1 investor

Shenzhen Dision Biomedical Technology, founded in 2019, develops, manufactures, sells, and services ophthalmic medical devices. Its R&D work spans optical design, mechanical structure machining, image recognition, neural-network deep learning, and big data, with research ties to Tsinghua University and domestic ophthalmology hospitals in China.

1 investor

Hangzhou Sumgen Biotech is a biopharmaceutical company that develops innovative antibody drugs, including monoclonal antibodies and antibody-drug conjugates (ADCs), for the treatment of cancer and other diseases. Its lead product, enlonstobart (Enshuxing®), received marketing approval from China's NMPA.

1 investor

A Chinese biotech company that uses proprietary synthetic biology to design, develop, and produce bioactive ingredients such as recombinant collagen and rare ginsenosides. Its output targets three areas: functional skincare products, medical devices, and functional/medical-purpose foods.

1 investor